Stock AnalizRegeneron Pharmaceuticals (REGN) earnings for the quarter ended September 2026: EPS beats estimates
Regeneron Pharmaceuticals reported results for the quarter ended September 2026 on October 30, 2026. Adjusted earnings per share came in at $20.07 against the analysts’ average forecast of $16.25, a beat of 23.5%.
Revenue for the quarter was $5.12 billion, up 36.3% from $3.75 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 13.3% on the first trading day after the report.
The last four quarters
Regeneron Pharmaceuticals has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $20.07 | $16.25 | +23.5% | +36% | +13.3% |
| Jun 2026 | $14.29 | $10.21 | +40.0% | +17% | +9.7% |
| Mar 2026 | $9.47 | $8.90 | +6.4% | +19% | −3.4% |
| Dec 2025 | $11.44 | $10.75 | +6.4% | +3% | −1.1% |
What comes next
Analysts expect EPS of $25.39 for the next quarter on average and $68.75 for the fiscal year ending December 31, 2026.
The average analyst price target is $977.93, 2% above the current price of $955.47.
Valuation and score
Regeneron Pharmaceuticals scores 3.2 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 21.1, and its intrinsic value under moderate assumptions is about 17% above the current market value. Full Regeneron Pharmaceuticals analysis with 10 years of financials
Frequently asked questions
What was Regeneron Pharmaceuticals’s EPS for the quarter ended September 2026?
$20.07 adjusted per share, against an analyst consensus of $16.25.
How much revenue did Regeneron Pharmaceuticals report?
$5.12 billion, up 36.3% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.